Compare RACC & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RACC | ANIX |
|---|---|---|
| Founded | N/A | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.8M | 119.8M |
| IPO Year | 2026 | 2013 |
| Metric | RACC | ANIX |
|---|---|---|
| Price | $21.40 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 54.7K | ★ 278.2K |
| Earning Date | N/A | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.39 | $2.32 |
| 52 Week High | $23.00 | $5.46 |
| Indicator | RACC | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 89.21 | 57.72 |
| Support Level | $10.44 | $2.90 |
| Resistance Level | N/A | $3.53 |
| Average True Range (ATR) | 0.97 | 0.29 |
| MACD | 0.46 | 0.00 |
| Stochastic Oscillator | 94.54 | 55.91 |
Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.